Cardiovascular Inflammation Reduction Trial

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 4786 participants.

Also called NCT01594333

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 4,786 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01594333
Other papers using this trial's data
  • Adverse Effects of Low-Dose Methotrexate: A Randomized Trial Annals of internal medicine, 2020-03-17 DOI, PubMed 32066146, PMC7229518 In the PMC Open Access subset under a licence that is not Creative Commons.
  • Adverse effects related to methotrexate polyglutamate levels: adjudicated results from the cardiovascular inflammation reduction trial Rheumatology (Oxford, England), 2021-06-18 DOI, PubMed 34144603, PMC8494062 Not in the PMC Open Access subset.
  • Blood pressure changes during methotrexate treatment: results from a randomized placebo-controlled trial among patients with cardiovascular risk Rheumatology (Oxford, England), 2025-06-01 DOI, PubMed 39657237, PMC12107077 Not in the PMC Open Access subset.
  • Comparison of interleukin-6, C-reactive protein, and low-density lipoprotein cholesterol as biomarkers of residual risk in contemporary practice: secondary analyses from the Cardiovascular Inflammation Reduction Trial European heart journal, 2020-08-14 DOI, PubMed 32221587, PMC7453833 Not in the PMC Open Access subset.
  • Effect of Low-Dose Methotrexate on eGFR and Kidney Adverse Events: A Randomized Clinical Trial Journal of the American Society of Nephrology : JASN, 2021-12-01 DOI, PubMed 34551998, PMC8638389 Not in the PMC Open Access subset.
  • Genetics are not likely to offer clinically useful predictions for elevated liver enzyme levels in patients using low dose methotrexate Seminars in arthritis and rheumatism, 2022-08 DOI, PubMed 35671649, PMC10782828 In the PMC Open Access subset under a licence that is not Creative Commons.
  • Methotrexate effects on adenosine receptor expression in peripheral monocytes of persons with type 2 diabetes and cardiovascular disease Journal of investigative medicine : the official publication of the American Federation for Clinical Research, 2022-08 DOI, PubMed 35606100
  • Pulmonary Adverse Events in Patients Receiving Low-Dose Methotrexate in the Randomized, Double-Blind, Placebo-Controlled Cardiovascular Inflammation Reduction Trial Arthritis & rheumatology (Hoboken, N.J.), 2020-12 DOI, PubMed 32741143, PMC7722048 In the PMC Open Access subset under a licence that is not Creative Commons.

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Canada, Puerto Rico (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01594333. Randomized; triple masking; primary purpose treatment. Start 2013-04 (registry gives no type); primary completion 2019-04-15 (actual). Results posted on 2020-07-24.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Cardiovascular Inflammation Reduction Trial
Acronym
CIRT
Condition
Cardiovascular Disease
Intervention (Drug)
Methotrexate
Intervention (Drug)
Placebo
Lead sponsor
Brigham and Women's Hospital (class: other)
Collaborator
National Heart, Lung, and Blood Institute (NHLBI) (class: US National Institutes of Health)

Record details

Record id
cardio:ct-nct01594333
Content hash
2aa8bc2ccd1f3b33f31779e5fef398613af5f213e26fbefaf07e1d5ec6862af0